Investigational Drug Information for Bifeprunox
✉ Email this page to a colleague
What is the drug development status for Bifeprunox?
Bifeprunox is an investigational drug.
There have been 20 clinical trials for Bifeprunox.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2005.
The most common disease conditions in clinical trials are Schizophrenia, Psychotic Disorders, and Depression. The leading clinical trial sponsors are Solvay Pharmaceuticals, Wyeth is now a wholly owned subsidiary of Pfizer, and H. Lundbeck A/S.
Summary for Bifeprunox
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,407 |
| WIPO Patent Applications | 592 |
| Japanese Patent Applications | 280 |
| Clinical Trial Progress | Phase 3 (2005-09-01) |
| Vendors | 37 |
Recent Clinical Trials for Bifeprunox
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy of Bifeprunox in Patients With Schizophrenia | H. Lundbeck A/S | Phase 3 |
| Efficacy of Bifeprunox in Patients With Schizophrenia | H. Lundbeck A/S | Phase 3 |
| Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
Clinical Trial Summary for Bifeprunox
Top disease conditions for Bifeprunox
Top clinical trial sponsors for Bifeprunox
US Patents for Bifeprunox
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
